The following is a summary of the Establishment Labs Holdings Inc. (ESTA) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Establishment Labs reported Q1 revenue of $37.2 million, and an adjusted EBITDA loss of less than $4 million, a significant improvement from a previous loss of $17 million.

• The first quarter gross profit was reported as $24.4 million, or 65.6% of revenue.

• SG&A expenses for Q1 declined approximately $2.8 million to $28.9 million.

• R&D expenses also declined by approximately $2.2 million to $4.3 million compared to the same quarter of the previous year.

• The net loss from operations for Q1 was $8.8 million.

• The cash position at the end of Q1 was $73 million, and revenue guidance for 2024 is set at $174 million to $184 million.

Business Progress:

• Establishment Labs launched Motiva implants in China and Flora tissue expander in the US.

• The company made significant progress towards US approval of Motiva implants.

• Mia Femtech is advancing, with new centers opening in the Middle East and Latin America.

• Establishment Labs has entered the Chinese market, and the pending US launch of Motiva implants is expected to significantly boost the company.

• The company is confident of achieving a revenue run rate of $1 million per Mia partner clinic and is continuing to expand its network in European and distributor markets.

More details: Establishment Labs IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.